Company: SRPT
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0000950170-25-103971
Chunk: 7

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part II, Item 2
Chunk 7
---
The following table contains information regarding our purchases of our common stock during the quarter.

     ISSUER PURCHASES OF EQUITY SECURITIES

     Period
      
     Total Number of Shares Purchased

     Average Price Paid per Share

     Total Number of Shares Purchased as Part of Publicly announced Plans or Programs (a)

     Approximate Dollar Value (in thousands) of Shares that May Yet Be Purchased Under the Plans or Programs (a)

     April 1-30, 2025

     —

     $
     —

     —

     $
     500,000

     May 1-31, 2025

     650,876

     38.41

     650,876

     475,000

     June 1-30, 2025

     —

     —

     —

     475,000

     Total

     650,876

     $
     38.41

     650,876

(a) All Common Stock repurchases during the quarter were made under the November 2024 authorization from our Board of Directors to purchase up to $500.0 million of our outstanding Common Stock.  See Note 10, Equity to our unaudited condensed consolidated financial statements included in this Quarterly Report for additional information.

Repurchases under the authorized stock repurchase program may be made using a variety of methods, which may include, but are not limited to, open market purchases, privately negotiated transactions, accelerated share repurchase agreements or purchases pursuant to a Rule 10b5-1 plan under the Securities Exchange Act of 1934, as amended. The authorization from our Board expires in May 2026 and may be suspended, delayed or discontinued at any time.

Item 3. Defaults Upon Senior Securities. 

None. 

Item 4. Mine Safety Disclosures. 

None. 

Item 5. Other Information. 

During the six months ended June 30, 2025, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. 

Item 6. Exhibits.